FDA
-
-
-
-
-
-
-
SCIENTURE receives patent for naloxone nasal spray through 2041
-
-
-
-
-
-
-
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
-
-
-
-
-
-
-
SCIENTURE reports 216% revenue growth in 2025 driven by Arbli launch
-
-
-
-
-
-
-
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
-
-
-
-
-
-
-
SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
-
-
-
-
-
-
-
Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements
-
-
-
-
-
-
-
Scienture Holdings (SCNX) Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health
-
325,901 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

